Drug Trial Radar · NCT07011797
A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants
Last checked: Nov 19, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
250
Actual
Start
Jun 17, 2025
Primary completion
Mar 23, 2026
Study completion Apr 9, 2026
Sponsor
- Lead sponsor
- Corxel PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jun 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study: * To evaluate the efficacy of different dose levels of CX11 tablets in body weight reduction as compared to placebo. * To compare the changes of effects in weight and weight-related indicators at the visit time points. * To evaluate the tolerability and safety of different doses of CX11 tablets in overweight/obese participants. * To assess the pharmacokinetics (PK) of different doses of CX11 tablets in overweight/obese participants. Overweight/obese participants who are successfully screened will be randomized in a 1:1:1:1:1 ratio to different doses of CX11 tablets or placebo. All participants will enter a 2-week follow-up period after 36 weeks of treatment for safety observation.
Conditions
- Obesity
Interventions
CX11Drug
CX11 tablets administered orally once daily (QD) with meals
PlaceboOther
Matching placebo tablets administered orally once daily (QD) with meals
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change in body weight from baselineTime frame: At Week 26
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
AES - DRS - Synexus Clinical Research US, Inc. - Phoenix Central
Phoenix, Arizona
310 Clinical Research - Alliance Clinical - Los Angeles
Inglewood, California
Acclaim Clinical Research - Alliance Clinical - San Diego
San Diego, California
Angels Clinical Research Institute - Miami
Doral, Florida
AES - DRS - Optimal Research Florida - Melbourne
Melbourne, Florida
Angels Clinical Research Institute
Miami, Florida
Palm Springs Community Health Center
Miami Lakes, Florida
Oceanic Research Group, LLC
North Miami Beach, Florida
Privia Medical Group Georgia, LLC - Savannah - Javara - PPDS
Savannah, Georgia
Privia Medical Group Georgia, LLC - Thomasville - Javara - PPDS
Thomasville, Georgia
Velocity Clinical Research - Valparaiso (Buynak Clinical Research) - PPDS
Valparaiso, Indiana
Mankato Clinic - East Main Street - Javara - PPDS
Mankato, Minnesota
Velocity Clinical Research - Cincinnati (Springdale) - Ohio - PPDS
Cincinnati, Ohio
Velocity Clinical Research - Dallas - PPDS
Dallas, Texas
Epic Clinical Research - Alliance Clinical - Lewisville
Lewisville, Texas
AES - DRS - Synexus Clinical Research US, Inc. - San Antonio
San Antonio, Texas
Flourish Research - San Antonio - PPDS
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.